Critical Care & Emergencies (all articles)
Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine
15 Apr, 2021 | 07:02h | UTCThrombotic Thrombocytopenia after Ad26.COV2.S Vaccination – New England Journal of Medicine
Related: U.S. regulators pause Johnson & Johnson vaccine rollout over rare (1 in a million) cases of blood clots AND 4 Things to Know About the J&J Covid Vaccine Pause – Kaiser Health News AND Why Johnson & Johnson shots were paused — and why that’s so confusing – Vox AND Is it the adenovirus vaccine technology, used by AstraZeneca and Johnson & Johnson, causing blood clots? There’s no evidence yet – The Conversation
New studies suggest SARS-CoV-2 variant B.1.1.7 is not more deadly, just more transmissible
14 Apr, 2021 | 02:12h | UTCCommentaries: Expert reaction to two papers looking at the transmissibility and severity of the B.1.1.7 variant – Science Media Centre AND UK coronavirus variant not more deadly, just spreads more easily, studies find – LiveScience
Study: Protocoled time-limited trials among critically ill patients with advanced medical illnesses were associated with reduction of nonbeneficial ICU treatments
13 Apr, 2021 | 05:16h | UTCEvaluation of Time-Limited Trials Among Critically Ill Patients With Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments – JAMA Internal Medicine (free for a limited period)
Commentary: Time-Limited Trials and Potentially Nonbeneficial Treatment in the ICU—Willing to Wait for It – JAMA Internal Medicine AND Time-limited trials may decrease the length of stay of critically ill patients in the intensive care unit – 2 Minute Medicine
Author interview: Time-Limited Trials Among Patients With Advanced Illness to Reduce Nonbeneficial ICU Treatments
Related review: Time-limited trial of intensive care treatment: an overview of current literature – Intensive Care Medicine
IDSA Guidance on the Treatment of ESBL Enterobacterales, Carbapenem-Resistant Enterobacterales, and Pseudomonas
13 Apr, 2021 | 05:11h | UTC
Long-term mortality of elderly patients after intensive care unit admission for COVID-19
14 Apr, 2021 | 02:09h | UTC
Commentary on Twitter
Long-term outcome of elderly (≥ 80y) #COVID19 pts admitted to #ICU: 6-month mortality ➡️ 72% (likely underestimated) at upper end of recent literature on older critical pts. Data supporting more informed goals-of-care decisions for this #SARSCoV2 cohort?https://t.co/mIKNxNpdC8 pic.twitter.com/OQS5SN5FXR
— Intens Care Med (@yourICM) April 13, 2021
RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19
13 Apr, 2021 | 05:30h | UTCOriginal study (preprint): Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial – medRxiv
Commentary: Covid: Asthma drug ‘speeds up recovery at home’ – BBC
Related study: Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 (study and commentaries)
Cohort Study: Effects of fluoroquinolones on outcomes of patients with aortic dissection or aneurysm
13 Apr, 2021 | 05:05h | UTCRelated: Another study suggests fluoroquinolone use may increase the risk of development of aortic aneurysms (study and commentaries) AND Link between fluoroquinolones, aorta problems may not be as strong as thought AND Study: Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation AND FDA Warns About Increased Risk of Aortic Dissection and Ruptures of Aortic Aneurism with Fluoroquinolones AND Meta-analysis: Fluoroquinolones and the Risk of Aortopathy AND Study: Oral Fluoroquinolone and the Risk of Aortic Dissection AND Research: Fluoroquinolone use and risk of aortic aneurysm and dissection
M-A: Post-extubation oxygenation strategies in acute respiratory failure – NPPV or HFNC may reduce the risk of endotracheal reintubation but not mortality
12 Apr, 2021 | 00:42h | UTC
AHA/ASA Scientific Statement: Perioperative Neurological Evaluation and Management to Lower the Risk of Acute Stroke in Patients Undergoing Noncardiac, Nonneurological Surgery
12 Apr, 2021 | 00:50h | UTC
Commentary on Twitter
NEW GUIDELINE – now codifies what has been discussed for a while "If history of stroke exists, consider delaying elective surgery at least 6 mo
and preferably 9 mo from time of incident stroke." @SPAQIedu @LeeAFleisher @preopconsult @afedwardMD https://t.co/0ewdlPGVlj— Kurt Pfeifer (@KurtPfeifer) April 9, 2021
Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19
13 Apr, 2021 | 05:21h | UTCRelated: Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery AND Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk
[Press release – not published yet] Phase 3 prevention trial showed 81% reduced risk of symptomatic SARS-CoV-2 infections with subcutaneous administration of monoclonal antibodies
13 Apr, 2021 | 05:26h | UTCCommentaries: Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV – STAT AND Regeneron’s Covid mAb as a prophylactic injection: Reduced risk of symptomatic infection by 81% – Endpoint News
Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients
12 Apr, 2021 | 01:23h | UTC
Commentary on Twitter
Prone position in #COVID19, use & effect:
➡️PP widely adopted, the more severe the respiratory failure, the more frequent the use
➡️PP improved oxygenation in most (better V/Q matching?)
➡️mortality of O2-Non-Responders significantly higher@Crit_Care https://t.co/Q2Z15a8Pvr pic.twitter.com/CZqshIfJrg— M Velia Antonini (@FOAMecmo) April 7, 2021
Another study shows intravenous radiocontrast use is not associated with reduced kidney function
12 Apr, 2021 | 00:44h | UTCCommentaries: Radiocontrast Exposure Safe for Kidney Function – HCP Live AND Exposure to contrast on CTPA doesn’t cause long-term kidney injury – AuntMinnie
Related: ACR/NKF Consensus Statement: “The Risk of Acute Kidney Injury Developing in Patients with Reduced Kidney Function Following Exposure to Intravenous Iodinated Contrast Media has Been Overstated” (Guideline and commentaries)
Commentary on Twitter (thread – click for more)
Our new paper in @JAMAInternalMed: is IV contrast nephrotoxic? Lots of studies say no, but have ⬆️risk of confounding: people who get contrast ≠ people who don't get it. We used a natural experiment to try to overcome this bias https://t.co/XWEEohAvK0 1/5
— Robert Goulden (@EMrobg) April 5, 2021
M-A: Treatment for bleeding esophageal varices in people with decompensated liver cirrhosis
12 Apr, 2021 | 00:39h | UTCRelated Cochrane Reviews: M-A: Secondary prevention of variceal bleeding in adults with previous esophageal variceal bleeding due to decompensated liver cirrhosis AND Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta‐analysis – Cochrane Library
Japanese doctors perform world’s first living donor lung transplant to a Covid-19 patient
12 Apr, 2021 | 01:12h | UTCJapanese doctors perform world’s first living donor lung transplant to a Covid-19 patient – CNN
Comprehensive Review | Pneumonia
9 Apr, 2021 | 03:14h | UTCPneumonia – Nature Reviews Disease Primers (free for a limited period)
Try this link if the above is paywalled.
Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19
12 Apr, 2021 | 01:24h | UTC
Commentary on Twitter
NEW Research— Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early #COVID19
RCT from Mona Bafadhel & colleagues https://t.co/6cJogJs7rp pic.twitter.com/C1dhmTcexP
— The Lancet Respiratory Medicine (@LancetRespirMed) April 10, 2021
[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil
9 Apr, 2021 | 03:36h | UTC
Commentary on Twitter (thread – click for more)
New 50% efficacy study of Brazil-predominant vaccine CoronaVac (by Sinovac) in Manaus ?? among healthcare workers when #P1 ~75% dominant. Not a trial, but the study found a 1st dose >=14-days efficacy of 50% on symptomatic #COVID19, ~32% if +asymptomatic. https://t.co/YMmZ3mmSDI pic.twitter.com/jwx5R627ys
— Eric Feigl-Ding (@DrEricDing) April 8, 2021
Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?
9 Apr, 2021 | 03:28h | UTC
The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19
9 Apr, 2021 | 03:35h | UTC
Review: Care for the organ transplant recipient on the intensive care unit
8 Apr, 2021 | 08:36h | UTCCare for the organ transplant recipient on the intensive care unit – Journal of Critical Care
Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials
8 Apr, 2021 | 08:59h | UTCCommentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly
Commentary on Twitter (thread – Click for more)
Interesting report on VTE incidence in COVID-19 patients, starting with counting outside of the hospital. See https://t.co/XJvbrfHm6d … 1/n
— Geert-Jan Geersing (@gjgeersing) April 7, 2021
ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections
6 Apr, 2021 | 01:12h | UTCSummary for Patients: Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians
Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination
7 Apr, 2021 | 01:48h | UTC
Commentary on Twitter
*CLINICIANS*
New guidance for suspected cases of thrombosis-thrombocytopaenia syndrome following COVID-19 vaccination. This is a very rare event but worth bookmarking as it also guides you on what is NOT likely to be a case.MT @Maherjane https://t.co/PHjFlB079y
— Trisha Greenhalgh ? #CovidIsAirborne (@trishgreenhalgh) April 6, 2021
Large study showed no association between blood group types and increased risk of Covid-19
7 Apr, 2021 | 01:41h | UTC
Commentary on Twitter
This case-control study found blood type A was not associated with higher nor type O with lower COVID-19 susceptibility or severity. Blood types were not prognostically useful. https://t.co/P8VpvQWuwE
— JAMA Network Open (@JAMANetworkOpen) April 6, 2021